Fig. 4From: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysisTime to progression. Kaplan–Meier estimates of time to progression by treatment group. TTP, time to progression; HR, hazard ratio; CI, confidence intervalBack to article page